Consenso Brasileiro de Espondiloartropatias: espondilite anquilosante e artrite psoriásica diagnóstico e tratamento - primeira revisão

Sampaio-Barros, Percival Degrava; Azevedo, Valderílio Feijó; Bonfiglioli, Rubens; Campos, Wesley Ribeiro; Carneiro, Sueli Coelho da Silva; Carvalho, Marcos Alberto de; Gonçalves, Célio Roberto; Hilário, Maria Odete Esteves; Keiserman, Mauro Waldemar; Leite, Nocy; Mallmann, Karen; Meirelles, Eduardo de Souza; Vieira, Walber Pinto; Ximenes, Antônio Carlos

doi:10.1590/s0482-50042007000400001

Cited by 30 publications

(22 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All of the patients were regularly followed at the Immunobiological Clinic of the Rheumatology Division of the Universidade Federal de São Paulo/Escola Paulista de Medicina (Brazil), and all of the patients demonstrated moderate to severe disease activity and had received anti-TNF-α therapy for the previous 6 months (19,20). The patients were evaluated in the same manner every 3 months, regardless of the type of TNF-blocker administration (i.e., intravenous or subcutaneous).…”

Section: Methodsmentioning

confidence: 99%

The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis

Machado¹,

Reis-Neto²,

Soares³

et al. 2013

Clinics

View full text Add to dashboard Cite

OBJECTIVE:We evaluated the incidence of and the main risk factors associated with cutaneous adverse events in patients with chronic inflammatory arthritis following anti-TNF-α therapy.METHODS:A total of 257 patients with active arthritis who were taking TNF-α blockers, including 158 patients with rheumatoid arthritis, 87 with ankylosing spondylitis and 12 with psoriatic arthritis, were enrolled in a 5-year prospective analysis. Patients with overlapping or other rheumatic diseases were excluded. Anthropometric, socioeconomic, demographic and clinical data were evaluated, including the Disease Activity Score-28, Bath Ankylosing Spondylitis Disease Activity Index and Psoriasis Area Severity Index. Skin conditions were evaluated by two dermatology experts, and in doubtful cases, skin lesion biopsies were performed. Associations between adverse cutaneous events and clinical, demographic and epidemiological variables were determined using the chi-square test, and logistic regression analyses were performed to identify risk factors. The significance level was set at p<0.05.RESULTS:After 60 months of follow-up, 71 adverse events (73.85/1000 patient-years) were observed, of which allergic and immune-mediated phenomena were the most frequent events, followed by infectious conditions involving bacterial (47.1%), parasitic (23.5%), fungal (20.6%) and viral (8.8%) agents.CONCLUSION:The skin is significantly affected by adverse reactions resulting from the use of TNF-α blockers, and the main risk factors for cutaneous events were advanced age, female sex, a diagnosis of rheumatoid arthritis, disease activity and the use of infliximab.

show abstract

Section: Methodsmentioning

confidence: 99%

The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis

Machado¹,

Reis-Neto²,

Soares³

et al. 2013

Clinics

View full text Add to dashboard Cite

show abstract

“…The MICA-002 allele, thus, might be a candidate for the development of PsA. 24 The following fi ndings have been reported: association of HLA-B27 with pustular psoriasis and acrodermatitis; association of HLA-B13 with guttate psoriasis; and increased frequencies of HLA-B17 in patients with erythrodermic psoriasis. 5 Although the event triggering the disease is not always recognized, an environmental "trigger" in a predisposed individual might be determinant, because in addition to the genetic factor, environmental and immune elements interact for disease onset.…”

Section: Genetic and Triggering Factorsmentioning

confidence: 99%

Artrite psoriásica: entidade clínica distinta da psoríase?

Ruiz¹,

Azevedo²,

Santos³

2012

Rev. Bras. Reumatol.

View full text Add to dashboard Cite

Psoriasis and psoriatic arthritis are complex and heterogeneous clinical entities, whose presentations comprise multiple combinations of subtypes. There are doubts even if they are distinct entities or merely variants of the same disease. Epidemiologically, psoriasis can be considered a common disease because it affects about 2% of the world population. Regarding psoriatic arthritis, there is no consensus in the literature about its true incidence and prevalence in the general population. Genetic, immune, and environmental factors interact culminating in skin and joint manifestations of psoriatic disease. The central role of activated T lymphocytes in the pathogenesis of both psoriasis and psoriatic joints is now recognized. Furthermore, proinfl ammatory cytokines can be found in increased concentrations in both skin and synovium of patients with psoriatic arthritis. Since 1964, when the relationship between psoriasis and psoriatic arthritis was recognized, many studies have been conducted to better understand the common mechanism of both diseases. The HLA has already been considered the center of the psoriatic arthritis immunopathogenesis; today, TNF-α plays such a role. This paper is a review of various factors associating psoriasis and psoriatic arthritis leading to the hypothesis of a single disease with multiple presentations.

show abstract

“…Of these patients, 47 who were diagnosed with ankylosing spondylitis confirmed by the Rheumatology Outpatient Clinic of FUNFARME according to mod-ified criteria of New York (Goie et al, 1985) and the Brazilian Consensus for the Diagnosis and Treatment of Spondyloarthropathies (Sampaio-Barros et al, 2007) were selected for this study. The main clinical signs obtained from the medical records were axial inflammatory pain (N = 47), bilateral sacroiliitis with grades ranging from 1 to 4 (N = 47), and asymmetric synovitis (N = 13).…”

Section: Selection Of Participantsmentioning

confidence: 99%

Lack of association of the G22A polymorphism of the ADA gene in patients with ankylosing spondylitis

Camargo

Cintra²,

Nunes³

et al. 2012

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Genes located outside the HLA region (6p21) have been considered as candidates for susceptibility to ankylosing spondylitis. We tested the hypothesis that the G22A polymorphism of the adenosine deaminase gene (ADA; 20q13.11) is associated with ankylosing spondylitis in 166 Brazilian subjects genotyped for the HLA*27 gene (47 patients and 119 controls matched for gender, age and geographic origin). The HLA-B*27 gene and the G22A ADA polymorphism were identified 1179 ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 11 (2): 1178-1184 (2012) Association between G22A ADA SNP and ankylosing spondylitis by PCR with sequence-specific oligonucleotide probes and PCR-RFLP, respectively. There were no significant differences in frequencies of ADA genotypes [odds ratio (OR) = 1.200, 95% confidence interval (CI) = 0.3102-4.643, P > 0.8] and ADA*01 and ADA*02 alleles (OR = 1.192, 95%CI = 0.3155-4.505, P > 0.8) in patients versus controls. We conclude that the G22A polymorphism is not associated with ankylosing spondylitis.

show abstract

Consenso Brasileiro de Espondiloartropatias: espondilite anquilosante e artrite psoriásica diagnóstico e tratamento - primeira revisão

Cited by 30 publications

References 55 publications

The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis

The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis

Artrite psoriásica: entidade clínica distinta da psoríase?

Lack of association of the G22A polymorphism of the ADA gene in patients with ankylosing spondylitis

Contact Info

Product

Resources

About